Silybin ameliorates lipid metabolism disorders in mice with non-alcoholic steatohepatitis
10.12092/j.issn.1009-2501.2023.03.001
- Author:
Zuhuan CAI
1
;
Taomei DENG
1
;
Naijie WEI
1
;
Guangji WANG
1
;
Jingwei ZHANG
1
;
Dan ZHU
2
;
Fei QIAN
2
Author Information
1. Key Laboratory of Drug Metabolism & Pharmacokinetics, China Pharmaceutical University
2. Jiangsu Provincial Hospital of Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine
- Publication Type:Journal Article
- Keywords:
lipid metabolism;
non-alcoholic steatohepatitis;
silybin
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(3):241-248
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the regulatory effects of silybin on hepatic lipid metabolism in mice with non -alcoholic steatohepatitis (NASH) induced by high - fat and high-cholesterol (HFHD) diet. METHODS: Mice were fed a HFHD diet to construct a NASH model, and serum levels of triacylglycerol (TAG), total cholesterol (T-CHO), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were measured using biochemical kits. H&E staining and oil red O staining were used to detect histopathological changes in the liver. Lipidomics was used to detect the alterations of hepatic lipid metabolism in NASH mice. RESULTS: Silybin significantly inhibited the increase of body weight, liver weight and abdominal fat, decreased serum T-CHO, TAG and LDL-C levels, improved hepatic lipid droplet accumulation and ballooning degeneration, and back-regulated hepatic palmitoleic acid (C16: 1) and polyunsaturated long-chain fatty acids (PUFAs) in NASH mice. CONCLUSION: Silybin possibly reduced hepatic lipid accumulation and lipotoxicity by modulating abnormal hepatic lipid metabolism in mice induced by HFHC diet.
